Neuralstem, Inc is advancing in Clinical Trials Reports for Stem Cell Treatment for Lou Gehrig's Disease

Neuralstem Inc. has recently updated, progress of its ongoing Phase I human clinical trial for treating ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia, USA. The Safety Monitoring Board has approved moving to the next cohort and transplantation of the fourth patient. The first cohort of patients have received five injections of the company's spinal cord stem cells on one side of the spinal cord. The second cohort of three patients will receive ten injections, five on each side of the cord.

FDA has approved Phase I clinical trial to evaluate the safety of Neuralstem's spinal cord stem cells in the treatment of ALS has been underway since January of this year. This trial will ultimately consist of up to 18 ALS patients, who will be examined at regular intervals post-surgery, with final review of the data to come six months after the last patient is treated.